Summary
Skin patches of a clonidine transdermal therapeutic system (clonidine-TTS) with a constant release rate of either 0.1 or 0.2 mg clonidine/24 h continuously over 7 days were used in 32 essential hypertensives. These self-adhesive drug delivery systems (3.5 cm2), which were affixed to the upper outer arm, were changed by the patients at weekly intervals.
During a mean observation period of 7 months (range 1–19 months) transdermal clonidine reduced the blood pressure from 162±15/107±5 mmHg to normal values (diastolic ≦95 mmHg) in 63% of our patients. However, chronic use of clonidine-TTS was accompanied by a high frequency of contact dermatitis (type IV allergy) in nearly half of our patients (n=15, 47%). In 11 of these 15 patients transdermal clonidine administration had to be stopped because of intolerable local skin reactions (pruritus, erythema, vesiculation, and/or infiltration). Subsequent patch testing with all components of clonidine-TTS was performed in eight cases. Whereas in seven cases an allergic contact dermatitis to clonidine was found, only one patient showed an allergy to another component of clonidine-TTS (polyisobutylene).
We conclude that this strikingly high incidence of local allergic skin reactions limits the use of clonidine-TTS in essential hypertension.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arndts D, Stähle H, Förster HJ (1981) Development of a RIA for clonidine and its comparison with reference methods. J Pharmacol Methods 6:295
Cronin E (1972) Reactions to contact allergens given orally or systemically. Br J Dermatol 86:104
Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, Clare RA, Murray S (1976) Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19:11
Ekenvall L, Forsbeck M (1978) Contact eczema produced by a β-adrenergic blocking agent (alprenolol). Contact Dermatitis 4:190
Frauenfelder FT (1982) Transdermal scopolamine precipitating narrow-angle glaucoma. N Engl J Med 307:1079
Freis ED, Materson BJ, Flamenbaum W (1983) Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. Am J Med 74:1029
Frishman W, Silverman R (1979) Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3: Comparative clinical experience and new therapeutic applications. Am Heart J 98:119
Garrett BN, Kaplan NM (1980) Clonidine in the treatment of hypertension. J Cardiovasc Pharmacol 2:61
Georgopoulos AJ, Markis A, Georgiadis H (1982) Therapeutic efficacy of a new transdermal system containing nitroglycerin in patients with angina pectoris. Eur J Clin Pharmacol 22:481
Graybiel A, Cramer DB, Wood CD (1982) Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat Space Environ Med 53:770
Groth H, Vetter H, Knüsel J, Boerlin HJ, Walger P, Baumgart P, Wehling M, Siegenthaler W, Vetter W (1983) Clonidin-TTS bei essentieller Hypertonie: Wirkung und Verträglichkeit. Schweiz Med Wochenschr 113:1841
Groth H, Vetter H, Knüsel J, Vetter W (1983) Allergic skin reactions to transdermal clonidine. Lancet II:850
Guidelines for the treatment of mild hypertension (1983) Memorandum from a WHO/ISH Meeting Lancet I:457
Hindson C (1977) Contact eczema from methyl salicylate reproduced by oral aspirin (acetyl salicyclic acid). Contact Dermatitis 3:348
Hypertension detection and follow-up program of a cooperative group. Five-year findings of the hypertension detection and follow-up program. II. Mortality by race, sex and age (1979). J Am Med Assoc 242:2572
Karim A (1983) Transdermal absorption of nitroglycerin from microseal drug delivery (MDD) system. Angiology 34:11
Lowenstein J (1980) Clonidine. Ann Intern Med 92:74
Maibach H (1975) Acute laryngeal obstruction presumed secondary to thiomersal (merthiolate) delayed hypersensitivity. Contact Dermatitis 1:221
McMahon FG, Weber MA (1983) Allergic skin reactions to transdermal clonidine. Lancet II:851
Multiple Risk Factor Intervention Trial Research Group (1982) Multiple risk factor intervention trial. Risk factor changes and mortality results. J Am Med Assoc 248:1465
Osterholm RK, Camoriano JK (1982) Transdermal scopolamine psychosis. J Am Med Assoc 247:3081
Popli S, Stroka G, Ing TS, Daugirdas JT, Norusis MJ, Hano JE, Gandhi VC (1983) Transdermal clonidine for hypertensive patients. Clin Ther 5:624
Shaw JE, Urquhart J (1981) Transdermal drug administration — a nuisance becomes an opportunity. Br Med J 283:875
Thompson RH (1983) The clinical use of transdermal delivery devices with nitroglycerin. Angiology 34:23
Urquhart J (1982) Rate-controlled drug dosage. Drugs 23:207
Weber MA, Drayer JIM, Brewer DD, Lipson JI (1984) Transdermal continuous antihypertensive therapy. Lancet I:9
Zaffaroni A (1978) Therapeutic systems: The key to rational drug therapy. Drug Metab Rev 8:191
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Groth, H., Vetter, H., Knüsel, J. et al. Transdermal clonidine application: Long-term results in essential hypertension. Klin Wochenschr 62, 925–930 (1984). https://doi.org/10.1007/BF01727445
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01727445